

Conflicts of interest of statement from [The Lancet](#) paper: Commercial organisations in bold.

RO'C, EB, IF, CW, and JS have nothing to disclose. JF reports personal fees from **Amgen, Bayer, Pfizer, Boehringer Ingelheim, Sanofi, and AstraZeneca**, outside the submitted work; and non-financial support from **Amgen, Bayer, and Pfizer**, outside the submitted work. BM reports grants from the Medical Research Council, British Heart Foundation, and the National Institute for Health Research Oxford Biomedical Research Centre during the conduct of the study, and grants from **Merck** outside the submitted work. CR report grants from the Medical Research Council and British Heart Foundation during the conduct of the study; and grants from **Merck**, outside the submitted work. JE reports grants from the Medical Research Council and the British Heart Foundation during the conduct of the study, and a grant from **Boehringer Ingelheim** outside the submitted work. LB reports grants from the Medical Research Council and the British Heart Foundation during the conduct of the study. **MK is an employee of a company** that has received study grants and consulting fees from **manufacturers of PCSK9 inhibitors** and treatments for lipid disorders, outside the submitted work. AT reports personal fees from **Amgen and Sanofi**, outside the submitted work. PR reports a research grant from **AstraZeneca** during the conduct of the study; and research grants from **Novartis, Pfizer, and Kowa**, outside the submitted work. CP reports a grant from **Merck**, outside the submitted work; and personal fees from **Merck, Pfizer, Sanofi, Amgen, and Daiichi-Sankyo**, outside the submitted work. EL reports grants from **AstraZeneca, Bayer, Boehringer Ingelheim, Amgen, and Merck**, outside the submitted work; and personal fees from **Bayer, Amgen, Novartis, and Sanofi**, outside the submitted work. WK reports grants and non-financial support from **Roche, Beckmann, Singulex, and Abbott**, outside the submitted work; and personal fees from **AstraZeneca, Novartis, Pfizer, The Medicines Company, GlaxoSmithKline, Dalcour, Sanofi, Berlin-Chemie, Kowa, and Amgen**, outside the submitted work. AG reports personal fees from **Aegerion Pharmaceuticals, Arisaph Pharmaceuticals, DuPont, Esperion Therapeutics, Kowa, Merck, Roche, Vatera Capital, ISIS Pharmaceuticals, Weill Cornell Medicine, and Amgen**, outside the submitted work. SY reports a grant from **AstraZeneca**, outside the submitted work. RC reports support from the Nuffield Department of Population Health, during the conduct of the study; grants from the British Heart Foundation, Cancer Research UK, Medical Research Council, **Merck**, National Institute for Health Research, and the Wellcome Trust, outside the submitted work; personal fees from the British Heart Foundation and UK Biobank, outside the submitted work; other support from **Pfizer** to the Nuffield Department of Population Health (prize for independent research); and a patent for a statin-related myopathy genetic test licensed to University of Oxford from **Boston Heart Diagnostics** (RC has waived any personal reward). CB reports grants from the Medical Research Council and British Heart Foundation, during the conduct of the study; and grants from **Pfizer, Merck, Novartis, and Boehringer Ingelheim**, outside the submitted work. AK reports grants from **Abbott and Mylan**, outside the submitted work; and personal fees from **Abbott, Amgen, AstraZeneca, Mylan, and Pfizer**, outside the submitted work. LB reports

grants from UK Medical Research Council and the British Heart Foundation during the conduct of the study.